Novogene Europe has expanded its single‑cell RNA sequencing capability at its Cambridge Omics Centre, bringing 10x Genomics Chromium‑based workflows closer to academic, biotech and biopharma researchers across the UK.
The development builds on the company’s established single‑cell expertise, including existing capability in Germany, and combines specialist project support, sequencing infrastructure and bioinformatics analysis to help researchers generate deeper biological insight from complex samples. It also follows the recent launch of Novogene Europe’s Untargeted Metabolomics Service and represents the next step in a broader phase of capability expansion at the site.
The Cambridge service initially focuses on 3′ gene expression using cells or nuclei, supported by GEM‑X chemistry, high‑throughput Illumina sequencing and Novogene Europe’s bioinformatics expertise.
It includes sample processing, quality control, library preparation, sequencing and comprehensive bioinformatics analysis, supporting research across oncology, immunology, neuroscience, stem cell biology, developmental biology and translational research, as well as biomarker and drug discovery.
By profiling gene expression at single‑cell or single‑nucleus resolution, researchers can explore cellular heterogeneity, identify rare populations and investigate how different cell types and states contribute to biological function. Beyond the new Cambridge capability, Novogene Europe’s wider portfolio includes 5′ gene expression and single‑cell immune profiling with T‑ and B‑cell receptor sequencing.
Tingting Zhou, VP of Novogene Europe, said: “Single‑cell sequencing is helping researchers study complex biological systems with a level of detail that is difficult to achieve using bulk approaches alone.” She added: “By expanding access to single‑cell sequencing workflows through our Cambridge Omics Centre, we are strengthening local support for UK researchers working across areas such as oncology, immunology, neuroscience, developmental biology and translational research.
This launch builds on Novogene Europe’s established single‑cell expertise and marks the next step in developing the Cambridge Omics Centre as a hub for advanced multiomics services. As Novogene marks its 15th anniversary year, we are pleased to continue expanding the scientific capabilities and bioinformatics support available to researchers across Europe.”
Kevin (Zhuocun) Lin, President of TusPark Holdings UK, explained: “We are delighted to see Novogene Europe continue to develop its capabilities at the TusPark Bio‑Innovation Centre, Cambridge Science Park. The expansion of single‑cell capability at the Cambridge Omics Centre further strengthens local research infrastructure and supports the growing community of academic, biotech and biopharma innovators in Cambridge.”
